Despina Thomaidou

Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Benjamin Solomon, Geoffrey Liu, Enriqueta Felip et al. · Journal of Clinical Oncology · 2024 · 255 citations · Full text

Selection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targeting

Sotiris Missailidis, Despina Thomaidou, K. Eszter Borbas et al. · Journal of Immunological Methods · 2004 · 41 citations

Autoimmune Disease, Immunology, Immunodominance +11

Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Laurence Albigès, Brian I. Rini, John B.A.G. Haanen et al. · Annals of Oncology · 2019 · 24 citations · Full text

Urology, Surgical Oncology, Genitourinary Cancer +8

Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry

Martin Boegemann, Marcus Hubbe, Despina Thomaidou et al. · Anticancer Research · 2018 · 23 citations · Full text

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial

Marc‐Oliver Grimm, Mototsugu Oya, Toni K. Choueiri et al. · European Urology · 2023 · 19 citations · Full text